Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Echo IQ Limited engages in the provision of artificial intelligence (AI) diagnostics tool that enhance the diagnosis of structural heart disease in Australia. It offers EchoSolv, provides an AI-powered risk assessment of structural heart disease, including aortic stenosis, diastolic dysfunction, and heart failure. The company was formerly known as Houston We Have Limited and changed its name to EchoIQ Limited in December 2021. Echo IQ Limited is based in Claremont, Australia.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Target Price
The average target price of EIQ.AX is 0.94 and suggests 66.4% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to in